Science 37 and Xperiome have entered into a partnership in order to allow for more viable rare disease research, according to an article in PR Newswire. If the partnership goes as planned, both companies will work together to bring research directly to the patients and to discover more clinical and real-world research opportunities. As rare diseases already face a dearth of investigation, this partnership is a positive sign for the community of those with rare conditions.

About the Partnership

Rare disease research has faced obstacles in the past; this is not up for debate. This partnership aims to overcome these challenges. By relieving patients of some of the burden that can come with a clinical trial, allowing the physicians of patients to work as investigators to further the research, and utilizing Xperiome’s Raremark, a patient-powered knowledge bank, the companies plan to make it easier to conduct rare disease research.

Two major aspects of this partnership are Science 37’s Decentralized Clinical Trial Operating System and Xperiome’s Raremark. Under the terms of the agreement, both companies will use technologies to increase patient’s access to available studies.  They will help to connect patients to possible studies and to run decentralized, quick trials.

Looking Forward

Overall, the goal of this partnership is to improve rare disease research by making it easier for patients to participate and removing any obstacles they may face. Not only does this facilitate research, but it will lead to the development of more treatments. Both companies look forward to the success of this partnership and hope that many patients reap the benefits.